Integrated DNA Technologies Expands into Clinical Diagnostics

This launch marks the company’s first in vitro diagnostic (IVD) offerings and its strategic entry into the NGS IVD market. Powered by the Archer platform technology, the IVD solutions are being introduced in the United States and select European countries. The launch is positioned to fill a gap for standardized workflows in oncology diagnostics and to support molecular pathology laboratories with quality, regulatory compliance, and clinical impact.

Both assays are built on IDT’s proprietary Anchored Multiplex PCR (AMP) chemistry, enabling targeted DNA and RNA sequencing with an emphasis on ease of use and laboratory efficiency. Each kit includes color‑coded, technician‑ and robot‑friendly reagents, adapters, and magnetic cleanup beads designed to simplify setup. In addition, key workflow steps can run in parallel, supporting efficient and straightforward library preparation for NGS.

Amid changing regulatory requirements in the United States and Europe, the introduction is intended to provide continuity for laboratories as they navigate increasingly complex biomarker landscapes in both routine and high‑stakes clinical settings. IDT plans to continue expanding its Archer IVD portfolio with future launches based on anchored multiplex PCR, aiming for broader access to Archer NGS assay capabilities, including novel fusion and complex variant detection for challenging sample types.

“At IDT, we believe that precision diagnostics should be as reliable as they are innovative,” said Ajay Gannerkote, president, IDT. “This launch reflects our commitment to supporting clinical labs with trusted solutions that combine innovative technology, ease-of-use, and regulatory assurance, so clinicians can focus on their mission-critical work to find the right answers across the expanding biomarker landscape.”

Related Links
Integrated DNA Technologies (IDT)